134 related articles for article (PubMed ID: 18501568)
1. Targeting of efavirenz loaded tuftsin conjugated poly(propyleneimine) dendrimers to HIV infected macrophages in vitro.
Dutta T; Garg M; Jain NK
Eur J Pharm Sci; 2008 Jul; 34(2-3):181-9. PubMed ID: 18501568
[TBL] [Abstract][Full Text] [Related]
2. Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro.
Dutta T; Agashe HB; Garg M; Balakrishnan P; Kabra M; Jain NK
J Drug Target; 2007 Jan; 15(1):89-98. PubMed ID: 17365278
[TBL] [Abstract][Full Text] [Related]
3. Targeting potential and anti-HIV activity of lamivudine loaded mannosylated poly (propyleneimine) dendrimer.
Dutta T; Jain NK
Biochim Biophys Acta; 2007 Apr; 1770(4):681-6. PubMed ID: 17276009
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, characterization and targeting potential of zidovudine loaded sialic acid conjugated-mannosylated poly(propyleneimine) dendrimers.
Gajbhiye V; Ganesh N; Barve J; Jain NK
Eur J Pharm Sci; 2013 Mar; 48(4-5):668-79. PubMed ID: 23298577
[TBL] [Abstract][Full Text] [Related]
5. Interactions between U-937 human macrophages and poly(propyleneimine) dendrimers.
Kuo JH; Jan MS; Lin YL
J Control Release; 2007 Jul; 120(1-2):51-9. PubMed ID: 17537537
[TBL] [Abstract][Full Text] [Related]
6. Tuftsin-AZT conjugate: potential macrophage targeting for AIDS therapy.
Fridkin M; Tsubery H; Tzehoval E; Vonsover A; Biondi L; Filira F; Rocchi R
J Pept Sci; 2005 Jan; 11(1):37-44. PubMed ID: 15635725
[TBL] [Abstract][Full Text] [Related]
7. Effect of surface capping on targeting potential of folate decorated poly (propylene imine) dendrimers.
Birdhariya B; Kesharwani P; Jain NK
Drug Dev Ind Pharm; 2015; 41(8):1393-9. PubMed ID: 25163759
[TBL] [Abstract][Full Text] [Related]
8. Formulation development and in vitro-in vivo assessment of the fourth-generation PPI dendrimer as a cancer-targeting vector.
Kesharwani P; Tekade RK; Jain NK
Nanomedicine (Lond); 2014 Oct; 9(15):2291-308. PubMed ID: 24593000
[TBL] [Abstract][Full Text] [Related]
9. Glycoconjugated peptide dendrimers-based nanoparticulate system for the delivery of chloroquine phosphate.
Agrawal P; Gupta U; Jain NK
Biomaterials; 2007 Aug; 28(22):3349-59. PubMed ID: 17459469
[TBL] [Abstract][Full Text] [Related]
10. Characterization and evaluation of amphotericin B loaded MDP conjugated poly(propylene imine) dendrimers.
Jain K; Verma AK; Mishra PR; Jain NK
Nanomedicine; 2015 Apr; 11(3):705-13. PubMed ID: 25596078
[TBL] [Abstract][Full Text] [Related]
11. Surface-engineered dendrimeric nanoconjugates for macrophage-targeted delivery of amphotericin B: formulation development and in vitro and in vivo evaluation.
Jain K; Verma AK; Mishra PR; Jain NK
Antimicrob Agents Chemother; 2015 May; 59(5):2479-87. PubMed ID: 25645852
[TBL] [Abstract][Full Text] [Related]
12. Ligand anchored dendrimers based nanoconstructs for effective targeting to cancer cells.
Gupta U; Dwivedi SK; Bid HK; Konwar R; Jain NK
Int J Pharm; 2010 Jun; 393(1-2):185-96. PubMed ID: 20382210
[TBL] [Abstract][Full Text] [Related]
13. Generation dependent cancer targeting potential of poly(propyleneimine) dendrimer.
Kesharwani P; Tekade RK; Jain NK
Biomaterials; 2014 Jul; 35(21):5539-48. PubMed ID: 24731713
[TBL] [Abstract][Full Text] [Related]
14. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.
Gatanaga H; Hayashida T; Tsuchiya K; Yoshino M; Kuwahara T; Tsukada H; Fujimoto K; Sato I; Ueda M; Horiba M; Hamaguchi M; Yamamoto M; Takata N; Kimura A; Koike T; Gejyo F; Matsushita S; Shirasaka T; Kimura S; Oka S
Clin Infect Dis; 2007 Nov; 45(9):1230-7. PubMed ID: 17918089
[TBL] [Abstract][Full Text] [Related]
15. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.
Berenguer J; González J; Ribera E; Domingo P; Santos J; Miralles P; Angels Ribas M; Asensi V; Gimeno JL; Pérez-Molina JA; Terrón JA; Santamaría JM; Pedrol E;
Clin Infect Dis; 2008 Oct; 47(8):1083-92. PubMed ID: 18781872
[TBL] [Abstract][Full Text] [Related]
16. Efavirenz-loaded polymeric micelles for pediatric anti-HIV pharmacotherapy with significantly higher oral bioavailability [corrected].
Chiappetta DA; Hocht C; Taira C; Sosnik A
Nanomedicine (Lond); 2010 Jan; 5(1):11-23. PubMed ID: 20025460
[TBL] [Abstract][Full Text] [Related]
17. Lactoferrin-conjugated dendritic nanoconstructs for lung targeting of methotrexate.
Kurmi BD; Gajbhiye V; Kayat J; Jain NK
J Pharm Sci; 2011 Jun; 100(6):2311-20. PubMed ID: 21491447
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK
HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898
[TBL] [Abstract][Full Text] [Related]
19. Poly(propyleneimine) dendrimer and dendrosome mediated genetic immunization against hepatitis B.
Dutta T; Garg M; Jain NK
Vaccine; 2008 Jun; 26(27-28):3389-94. PubMed ID: 18511160
[TBL] [Abstract][Full Text] [Related]
20. In vivo toxicity of poly(propyleneimine) dendrimers.
Ziemba B; Janaszewska A; Ciepluch K; Krotewicz M; Fogel WA; Appelhans D; Voit B; Bryszewska M; Klajnert B
J Biomed Mater Res A; 2011 Nov; 99(2):261-8. PubMed ID: 21976451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
